Ajanta Pharma net profit increases 66 percent to Rs 203 crore in Q4
New Delhi: Ajanta Pharma witnessed a surge in its consolidated net profit, which soared by 66 percent to Rs 203 crore in the March quarter. This growth was attributed to strong sales performance in both domestic and international markets.
The drugmaker had reported a net profit of Rs 122 crore in the January-March quarter of the previous fiscal.
Ajanta Pharma is a speciality pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa. The company has a ground presence in each of these 30+ countries.
The company’s state-of-the-art R&D centre is located in Mumbai. The company has 7 world-class manufacturing facilities located in India. For the last 5 financial years, the company has posted healthy performance with its Revenue from Operations growing at 16% CAGR and net profit at 11% CAGR.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd